Remco A Koster1, Herman Veenhof1, Rixt Botma1, Alle Tjipke Hoekstra1, Stefan P Berger2, Stephan Jl Bakker2, Jan-Willem C Alffenaar1, Daan J Touw1,3. 1. University of Groningen, Department of Clinical Pharmacy & Pharmacology, University Medical Center Groningen, Groningen, The Netherlands. 2. University of Groningen, Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, Groningen, The Netherlands. 3. University of Groningen, Department of Pharmacy, Section Pharmacokinetics, Toxicology & Targeting, Groningen, The Netherlands.
Abstract
AIM: Hematocrit (Ht) effects remain a challenge in dried blood spot (DBS) sampling. The aim was to develop an immunosuppressant DBS assay on two LC-MS/MS systems covering a clinically relevant Ht range without Ht correction. RESULTS: The method was partially validated for tacrolimus, sirolimus, everolimus, cyclosporin A and fully validated for mycophenolic acid on an Agilent and Thermo LC-MS/MS system. Bias caused by Ht effects were within 15% for all immunosuppressants between Ht levels of 0.23 and 0.48 l/l. Clinical validation of DBS versus whole blood samples for tacrolimus and cyclosporin A showed no differences between the two matrices. CONCLUSION: A multiple immunosuppressant DBS method without Ht correction, has been validated, including a clinical validation for tacrolimus and cyclosporin A, making this procedure suitable for home sampling.
AIM: Hematocrit (Ht) effects remain a challenge in dried blood spot (DBS) sampling. The aim was to develop an immunosuppressant DBS assay on two LC-MS/MS systems covering a clinically relevant Ht range without Ht correction. RESULTS: The method was partially validated for tacrolimus, sirolimus, everolimus, cyclosporin A and fully validated for mycophenolic acid on an Agilent and Thermo LC-MS/MS system. Bias caused by Ht effects were within 15% for all immunosuppressants between Ht levels of 0.23 and 0.48 l/l. Clinical validation of DBS versus whole blood samples for tacrolimus and cyclosporin A showed no differences between the two matrices. CONCLUSION: A multiple immunosuppressant DBS method without Ht correction, has been validated, including a clinical validation for tacrolimus and cyclosporin A, making this procedure suitable for home sampling.
Authors: Tom C Zwart; Sumit R M Gokoel; Paul J M van der Boog; Johan W de Fijter; Dina M Kweekel; Jesse J Swen; Henk-Jan Guchelaar; Dirk Jan A R Moes Journal: Br J Clin Pharmacol Date: 2018-10-15 Impact factor: 4.335
Authors: A E C A B Willemsen; L M Knapen; Y M de Beer; R J M Brüggemann; S Croes; C M L van Herpen; N P van Erp Journal: Eur J Clin Pharmacol Date: 2017-12-08 Impact factor: 2.953
Authors: Herman Veenhof; Job Frank Martien van Boven; Anna van der Voort; Stefan Philip Berger; Stephanus Johannes Leonardus Bakker; Daniël Johannes Touw Journal: Br J Clin Pharmacol Date: 2020-02-28 Impact factor: 4.335
Authors: Marith I Francke; Laura E J Peeters; Dennis A Hesselink; Sanne M Kloosterboer; Birgit C P Koch; Herman Veenhof; Brenda C M de Winter Journal: Ther Drug Monit Date: 2022-05-23 Impact factor: 3.118
Authors: Tanja R Zijp; Zamrotul Izzah; Daan J Touw; Job F M van Boven; Christoffer Åberg; C Tji Gan; Stephan J L Bakker Journal: Drugs Date: 2021-11-01 Impact factor: 9.546